
Strides Pharma Science Limited has informed the Exchange regarding a press release dated October 04, 2023, titled "Strides receives USFDA approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate tablets".
Filed with NSE ·

Strides Pharma Science Limited has informed the Exchange regarding a press release dated October 04, 2023, titled "Strides receives USFDA approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate tablets".
6ix hasn’t read this filing yet.
Strides Pharma Science Ltd on 6ix
Follow Strides Pharma Science into a list and get an email when it puts out news.
Follow Strides Pharma Science